Anti RIP 3

Figure 1 Western Blot Validation in Human Cell Lines
Loading: 15 μg of lysates per lane.Antibodies: RIP3 2283, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 2 Western Blot Validation in C2C12 Cells Mouse
Loading: 15 μg of lysates per lane.Antibodies: RIP3 2283, 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane 1: 2283, 0.1 μg/mL in the presence of peptide blockingLane 2: 2283, 0.1 μg/mLLane 3: 2283, 0.2 μg/mLLane 4: 2283, 0.5 μg/mL

Figure 3 Western Blot Validation in Mouse Cell lines
Loading: 15 μg of lysates per lane.Antibodies: RIP3 2283, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 4 Immunohistochemistry Validation of RIP3 in Mouse Kidney Tissue
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-RIP3 antibody (2283) at 2.5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4℃. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Figure 5 Immunohistochemistry Validation of RIP3 in Rat Kidney Tissue
Immunohistochemical analysis of paraffin-embedded rat kidney tissue using anti-RIP3 antibody (2283) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4℃. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Figure 6 Immunofluorescence Validation of RIP3 in Rat Kidney Tissue
Immunofluorescent analysis of 4% paraformaldehyde-fixed Rat Kidney tissue labeling RIP3 with 2283 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Figure 7 KO Validation of RIP3 in RIP3 KO Mice (He et al., 2009)
Western blot analysis of RIP3 with anti-RIP3 antibodies shows disrupted RIP3 expression in pancreas, liver spleen thymus and lung of RIP3 KO mice. Cerulein treatment upregulated RIP3 expression in the pancreas of WT mice.

Figure 8 Immunohistochemistry Validation of RIP3 in Fadd KO mice (Zhang et al., 2011)
RIP3 expression detected by anti-RIP3 antibodies (2283) was decreased in Fadd KO mice as compared to WT mice.

Figure 9 KO Validation of RIP3 in MEF Cells (He et al., 2012)
Western blot analysis of RIP3 with anti-RIP3 antibodies shows disrupted RIP3 expression in RIP3 KO MEFs, but not in WT MEF cells.

Figure 10 KD Validation of RIP3 in L929 Cells (Narayan et al., 2012)
Immunoblot analysis of RIP3 with anti-RIP3 antibodies (2283) shows RIP3 expression was disrupted in RIP3 knockdown L929 cells.